News

News

November 14, 2022
AnaptysBio Recognized in BioSpace’s 2023 Best Places to Work
SAN DIEGO, November 14, 2022 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has been named a BioSpace 2023 Best Place to Work. BioSpace recognized 30 life sciences companies in the small
November 9, 2022
AnaptysBio to Participate in Upcoming November Investor Conferences
SAN DIEGO , Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga , chief executive officer of AnaptysBio , will represent the company in a fireside chat at
September 12, 2022
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
SAN DIEGO , Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that the company has sold its royalty interest on future global net sales of Zejula to a wholly-owned
Displaying 1 - 10 of 17